Monte Rosa Therapeutics
Stock Forecast, Prediction & Price Target
Monte Rosa Therapeutics Financial Estimates
Monte Rosa Therapeutics Revenue Estimates
Monte Rosa Therapeutics EBITDA Estimates
Monte Rosa Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $6.47M Low: $2.02M High: $8.97M avg. 0% | Avg: $17.78M Low: $4.14M High: $28.00M avg. 174.77% | Avg: $171.61M Low: $40.01M High: $270.24M avg. 865.16% | Avg: $348.52M Low: $81.27M High: $548.84M avg. 103.08% |
Net Income
% change YoY
| $-71.94M N/A | $-104.61M -45.41% | $-135.35M -29.37% | Avg: $-160.33M Low: $-121.29M High: $-67.33M avg. -18.46% | Avg: $-184.79M Low: $-189.65M High: $-68.35M avg. -15.25% | Avg: $-20.12M Low: $-35.15M High: $-63.48K avg. 89.11% | Avg: $58.24M Low: $183.77K High: $101.77M avg. 389.48% |
EBITDA
% change YoY
| $-72.72M N/A | $-112.50M -54.70% | $-137.08M -21.85% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.55 N/A | -$2.22 -43.22% | -$2.63 -18.46% | Avg: -$1.98 Low: -$2.36 High: -$1.31 avg. 24.77% | Avg: -$1.98 Low: -$3.69 High: -$1.33 avg. 0.15% | Avg: -$0.39 Low: -$0.68 High: -$0 avg. 80.18% | Avg: $1.13 Low: $0 High: $1.98 avg. 389.48% |
Operating Expenses
% change YoY
| $72.88M N/A | $112.38M 54.19% | $143.31M 27.51% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Monte Rosa Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 111.22% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -121.29M, average is -160.33M and high is -67.33M.
What is Monte Rosa Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 285.75% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $2.02M, average is $6.47M and high is $8.97M.
What is Monte Rosa Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 123.64% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$2.36, average is -$1.98 and high is $-1.31.